PPARG and Insulin resistance: Despite their low PPARγ transactivation activity, these partial agonists lower insulin resistance in vivo without side effects of TZD, possibly by interfering CDK5 (cyclin-dependent kinase 5)-mediated Ser245 phosphorylation at the helix 2-2’ link of hPPARγ, recruiting different co-activators and co-repressors (Hughes, et al, 2014; Dias et al, 2020), or indirectly stabilizing helix 12 (Bruning et al, 2007; Choi et al, 2010; Choi et al, 2011; Chrisman, et al, 2018; Hughes, et al, 2014).